The effect of moderate-intensity interval training on health indicators in women with nonalcoholic fatty liver disease

Effects of eight weeks of moderate-intensity interval training on inflammatory markers in women with nonalcoholic fatty liver disease: A randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250915067255N1

Enrollment

Registered

2025-10-04

Start date

2024-10-06

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Control group: The control group will not receive any exercise or educational intervention and will continue their daily activities. Intervention 2: Intervention group: Intervention gr

Eligibility

Sex/Gender

Female

Age

30 Years to 50 Years

Inclusion criteria

Inclusion criteria: Female gender Suffering from fatty liver (grade 1 or 2, confirmed by ultrasound and doctor) Overweight or obesity (body mass index between 25 and 35) No history of taking medications related to the liver or metabolism

Exclusion criteria

Exclusion criteria: Having regular exercise in the last three months Occurrence of medical problems or sports injuries during the study Taking certain medications Having certain diseases (cardiovascular, respiratory, renal, metabolic, and cancer diseases) Failure to attend more than 3 training sessions

Design outcomes

Primary

Measure	Time frame
Interleukin-6. Timepoint: Before and after the intervention. Method of measurement: Serum interleukin-6 (IL-6) concentration was measured using the Immulite IL-6 kit and an immunochemical method based on the Immulite 2000 system.;C-reactive protein. Timepoint: Before and after the intervention. Method of measurement: C-reactive protein (CRP) levels were measured using the CRP-H917-S kit manufactured by Delta Pars Company and by latex immunoturbidimetric method.;Cortisol. Timepoint: Before and after the intervention. Method of measurement: Cortisol levels were measured using the fully automated IMMULITE 2000XPi instrument. This instrument uses the electrochemiluminescence chemistry method. The kits used by the manufacturer are specifically designed for this instrument and comply with international standards.	—

Measure

Time frame

Interleukin-6. Timepoint: Before and after the intervention. Method of measurement: Serum interleukin-6 (IL-6) concentration was measured using the Immulite IL-6 kit and an immunochemical method based on the Immulite 2000 system.;C-reactive protein. Timepoint: Before and after the intervention. Method of measurement: C-reactive protein (CRP) levels were measured using the CRP-H917-S kit manufactured by Delta Pars Company and by latex immunoturbidimetric method.;Cortisol. Timepoint: Before and after the intervention. Method of measurement: Cortisol levels were measured using the fully automated IMMULITE 2000XPi instrument. This instrument uses the electrochemiluminescence chemistry method. The kits used by the manufacturer are specifically designed for this instrument and comply with international standards.

—

Secondary

Measure	Time frame
Fasting blood sugar. Timepoint: Before and after the intervention. Method of measurement: Measurements were performed using glucose kits and automated analyzers.;Maximum aerobic power. Timepoint: Before and after the intervention. Method of measurement: Rockport test.;Body composition. Timepoint: Before and after the intervention. Method of measurement: Measurements were taken using scales, a height scale, body mass index (BMI), and a body composition assessment device.;Lipid profile. Timepoint: Before and after the intervention. Method of measurement: Measurements were performed using the relevant kits and automated analyzers.;Liver enzymes. Timepoint: Before and after the intervention. Method of measurement: Measurements were performed using the relevant kits and automated analyzers.;Fasting blood insulin. Timepoint: Before and after the intervention. Method of measurement: Fasting insulin levels were measured using a human ELISA kit according to the manufacturer's instructions.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before and after the intervention. Method of measurement: Measurements were performed using glucose kits and automated analyzers.;Maximum aerobic power. Timepoint: Before and after the intervention. Method of measurement: Rockport test.;Body composition. Timepoint: Before and after the intervention. Method of measurement: Measurements were taken using scales, a height scale, body mass index (BMI), and a body composition assessment device.;Lipid profile. Timepoint: Before and after the intervention. Method of measurement: Measurements were performed using the relevant kits and automated analyzers.;Liver enzymes. Timepoint: Before and after the intervention. Method of measurement: Measurements were performed using the relevant kits and automated analyzers.;Fasting blood insulin. Timepoint: Before and after the intervention. Method of measurement: Fasting insulin levels were measured using a human ELISA kit according to the manufacturer's instructions.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Abbas Monazzami

Razi University of Kermanshah

monazzai.amirabbas@gmail.com+98 83 3427 7605

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026